Immigration status and utilization of secondary preventive treatment after ischemic stroke.
| Autor: | Mkoma GF; Danish Research Center for Migration, Ethnicity and Health, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Johnsen SP; Danish Center for Clinical Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark., Iversen HK; Stroke Center Rigshospitalet, Department of Neurology, University of Copenhagen, Copenhagen, Denmark., Andersen G; Danish Stroke Center, Department of Neurology, Aarhus University Hospital, Aarhus University, Aarhus, Denmark., Norredam M; Danish Research Center for Migration, Ethnicity and Health, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European stroke journal [Eur Stroke J] 2022 Dec; Vol. 7 (4), pp. 402-412. Date of Electronic Publication: 2022 Jul 11. |
| DOI: | 10.1177/23969873221111870 |
| Abstrakt: | Introduction: The objective of the study was to assess use and persistence of secondary preventive treatment after ischemic stroke comparing immigrants and Danish-born residents. Patients and Methods: A cohort of patients discharged with ischemic stroke (IS) diagnosis ( n = 106,224) by immigration status was identified from the Danish Stroke Registry between 2005 and 2018. We investigated use (claiming at least one prescription in 180 days post-discharge according to information from the Register of Medicinal Products Statistics) and persistence of treatment within 180 days thereafter using multivariable logistic regression and Fine and Gray models. Results: Overall, 82,078 Danish-born residents (80.6%) and 3589 (80.7%) immigrants with IS used at least one of the recommended preventive medications post-discharge. Immigrants had lower odds of use of anticoagulants and angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB) (odds ratio (OR), 0.66; 95% confidence interval (CI), 0.53-0.82 and OR, 0.87; 95% CI, 0.75-0.98, respectively) but had higher odds of use of beta-blockers (OR, 1.25; 95% CI, 1.02-1.53) than Danish-born residents after adjustment for age at stroke, sex, sociodemographic factors, duration of residence, stroke severity, and comorbidities. The odds were most evident among immigrants originating from non-Western countries. Persistence of medication use did not differ between immigrants and Danish-born residents after adjustment for sociodemographic factors and comorbidities. Conclusion: Modest disparities in use of standard guideline recommended secondary preventive medications were observed when comparing immigrants and Danish-born residents with ischemic stroke. Furthermore, no differences in persistence of medication therapy were observed. Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© European Stroke Organisation 2022.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|